Cerevel Therapeutics Earning Date (CERE)

USA |NASDAQ |USD

CERE Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 9, 2022 Jun 2022 - - $-0.42
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 9, 2022 Jun 2022 - - $0.00

Cerevel Therapeutics's next earnings date is Tuesday, Aug 9, 2022 for the fiscal quarter ending Jun 2022.

CERE Earnings Date & History Chart

CERE Earnings & Revenue Forecast

CERE Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $-1.80 $-2.08 $-1.54

CERE Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-1.78 $-1.86 $-1.84

CERE Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $0.00 $0.00 $0.00

CERE Earnings Date & Revenue History

CERE Earnings History

|
Show More
Show More

CERE Revenue History

|
Show More
Show More

Cerevel Therapeutics Next Earnings Date & Report

CERE Next Earnings Date & Report Preview: Jun 2022 (FQ)

CERE's next earnings date is Tuesday, Aug 9, 2022 for the fiscal quarter ending Jun 30, 2022.

Cerevel Therapeutics Previous Earnings Dates & Reports

CERE Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Cerevel Therapeutics's previous earnings date was May 10, 2022 for its fiscal quarter ended Mar 31, 2022.

CERE Previous Earnings Date & Report Recap: Dec 2021 (FY)

Cerevel Therapeutics's previous annual earnings date was Mar 1, 2022 for its fiscal year ended Dec 31, 2021.

CERE's earnings per share (EPS) was $-1.65, missing the consensus analysts forecast of $-1.63 by 1.23% , and lower than the previous year's EPS (Dec 2020) by 292.20%.

Revenues were $0.00.

The company reported a net income of $-225.33M.

Cerevel Therapeutics reported a free cash flow of $-189.05M for its fiscal year, compared to $-136.69M a year ago.

The company ended the fiscal year with $41.42M in total debt, an increase of 25.50% compared to the previous year.